Drug Profile
ASN 90
Alternative Names: ASN-120290; ASN-561; ASN-90Latest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator Asceneuron
- Class Neuroprotectants; Small molecules
- Mechanism of Action Hexosaminidase C inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Progressive supranuclear palsy
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for phase-I development in Progressive-supranuclear-palsy(In volunteers) in Switzerland (PO)
- 22 Feb 2023 Ferrer enters into a worldwide licensing agreement with Asceneuron to obtain rights for the development and commercialisation of ASN 90 in progressive supranuclear palsy
- 22 Feb 2023 Ferrer plans a phase II trial for Progressive supranuclear palsy (PO)